Synektik SA Adjusts Valuation Amid Strong Profitability and Growth Metrics

Synektik SA, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment reflecting its current market position. The company's valuation score has been revised, indicating a shift in its financial metrics. Notably, the P/E ratio stands at 21, while the Price to Book Value is recorded at 11.31. The EV to EBIT and EV to EBITDA ratios are 15.95 and 13.86, respectively, showcasing the company's operational efficiency. In terms of profitability, Synektik SA demonstrates a robust Return on Capital Employed (ROCE) of 84.69% and a Return on Equity (ROE) of 54.71%, highlighting its effective use of capital. The PEG ratio is noted at 0.73, suggesting a favorable valuation relative to growth expectations. Additionally, the company maintains a dividend yield of 3.25%, which may appeal to income-focused investors. Despite a flat financial performance in the last quarter of December 2025, Synektik SA's long-term fundamentals remain strong, with a compound annual growth rate (CAGR) of 69.14% in operating profits. This adjustment in evaluation reflects the company's ongoing commitment to maintaining a competitive edge in the industry. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.